Pharmaceutical Fill and Finish Outsourcing Market to Garner USD 4,010.51 million, Globally, by 2028 at 6.1% CAGR: The Insight Partners

The pharmaceutical fill and finish outsourcing market is projected to reach US$ 4,010.51 million by 2028 from US$ 2,657.04 million in 2021; it is expected to register a CAGR of 6.1% from 2021 to 2028.

The report highlights the key factors driving the market growth and prominent players with their developments in the market.

The rising demand from pharmaceutical and biopharmaceutical industries to meet the demand for fill/finish gap is expected to drive the market growth. According to the US Food and Drug Administration's (FDA's) Centre for Drug Evaluation and Research (CDER), biologics have accounted for 20% to 29% of approvals of new molecular entities (NMEs) in 2020. In 2019, small molecules accounted for 79% of all NME approvals, representing 38 of the 48 NMEs approved by the FDA and biologics accounted for 10 of the 48 NMEs approved or 21% of all NME approvals. In 2018, small molecules accounted for 71% of NME approvals and biologics 29% of NME approvals. In-house capacities companies sometimes lack the ability to manufacture new products. This factor supports the growth of the market. Specialized capabilities, such as lyophilisation, filling prefilled syringes and cartridges, or novel therapeutics, require unique manufacturing techniques that biotech technology companies find beneficial to outsource from contract manufacturing organizations, as they are cost-effective. Companies with in-house aseptic fill-and-finish capacity outsource on average 39% of their fill-and-finish needs.

Get Sample PDF Copy of Pharmaceutical Fill and Finish Outsourcing Market at: https://www.theinsightpartners.com/sample/TIPRE00017482/

North America is likely to continue its dominance in the pharmaceutical fill and finish outsourcing market during 2021-2028. The US holds the largest share of the market in North America and is expected to continue this trend during the forecast period. Automation advancements such as robotics have been one of the areas of progress for the US fill/finish operations. This primarily reduces the contamination risk to a great extent, thus aiding the regional growth. The overall integration of the supply chain that reduces human interactions is driving the pharmaceutical fill and finish outsourcing market growth. For instance, ABL adopted automation in their fill/finish operations in 2017. The company completed an expansion of aseptic fill/finish operations at its GMP bio manufacturing facility in Rockville, MD. The company installed a fully automated vial filling system. Such factors are expected to aid the growth of the overall pharmaceutical fill and finish outsourcing market.

Market Insights
Surge in Demand for Biological Products
The rising pipeline of biologic drugs and the increasing preference for such therapeutic interventions are expected to drive the demand for pharmaceutical fill and finish outsourcing during the forecast period. Approximately 60% of fill/finish services involve the clinical and commercial-scale packaging of anti-COVID-19 vaccines. Expansion of facilities is one of the critical factors that biopharma companies are considering during the pandemic. Biopharmaceutical companies are facing issues such as the aforementioned changes and budgetary constraints. Outsourcing is required to overcome these issues and meet the demands of biological products. The outsourcing of biopharmaceutical products from the contract manufacturing organizations is expected to drive the pharmaceutical fill and finish outsourcing industry over the next seven years. Approximately 90% of the installed fill/finish capacity belongs to market participants with commercial-scale production capabilities. Over 85% of the available fill and finish capacity belongs to large-scale companies.

State of Finished Products-Based Insights
Based on state of finished products, the pharmaceutical fill and finish outsourcing market is segmented into solids, semi-solids, and liquids. The liquid segment captured the largest share in 2021 and is expected to continue a similar trend over the forecast period. Growing demand for prefilled syringes and vials in the plastic syringe industries is expected to drive the demand for pharmaceutical fill and finish outsourcing. Application demand of vials in lyophilization is fuelling the growth of the fill and finish services market. Also, the rising number of new entrants in global biologics manufacturing results in the surge in outsourcing activities. Such a factor is anticipated to assist the global pharmaceutical fill and finish outsourcing market.

The COVID-19 pandemic disrupted various trades and businesses worldwide. Several regions such as North America, Europe, and RoW experienced an economic downturn dramatically. However, the pandemic also offered lucrative opportunities for the pharmaceutical and biopharmaceutical companies to strengthen their research and development. For instance, accelerating demand for new treatments for COVID-19 or other much-needed medicines requires high volume capacity production. Therefore, many pharmaceutical companies approach sponsor partners such as contract development and manufacturing organizations (CDMOs) and contract manufacturing organizations (CMOs) for scaling their production and fulfilling capacity demands at commercial levels. Additionally, with rising price levels of raw materials, pharmaceutical companies approach CMOS for benefits such as meeting short-level demand arising from the market and addressing offshore supply issues. Such factors have a positive impact on the market growth during the analysis period from 2021 to 2028.

Have Question? Speak to Analyst at:
https://www.theinsightpartners.com/speak-to-analyst/TIPRE00017482/?utm_source=OpenPR&utm_medium=10408

Pharmaceutical Fill and Finish Outsourcing Market: Competitive Landscape and Key Developments
Abbott, Teva Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd, Piramal Enterprises Ltd, MabPlex International Ltd, Wockhardt, Cytovance Biologics, Thermo Fischer Scientific Inc. (Patheon N.V.), and Boehringer Ingelheim International GmbH are among the leading companies operating in the pharmaceutical fill and finish outsourcing market.
Based on state of finished product, the pharmaceutical fill and finish outsourcing market is segmented into solids, semi-solids, and liquids. The liquids segment is likely to account for a large market share during 2021-2028.

By content, the pharmaceutical fill and finish outsourcing market is segmented into organic substances isolated from animal origin, organic substances isolated from microorganisms, and inorganic substances. The organic substances isolated from the microorganisms segment held a considerable share of the market in 2021 and is likely to continue its dominance in the market during the forecast period.

Order a Copy of Pharmaceutical Fill and Finish Outsourcing Market Shares, Strategies and Forecasts 2021-2028 Research Report at: https://www.theinsightpartners.com/buy/TIPRE00017482/?utm_source=OpenPR&utm_medium=10408

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876

About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defence, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.